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Abstract The functionally important regions of the cyclic pen-
tapeptide endothelin A receptor antagonist BQ123 are shown to 
correlate with the structure of the C-terminal tail of endothelin-1, 
as found in the recently-determined X-ray crystal structure. Res-
idues 18 and 21 of endothelin-1 are spatially juxtaposed such that 
they superpose extremely well with o-Asp and o-Trp of the antag-
onist, consistent with the residues on this surface of the endothelin 
helix being important for binding. This study provides new infor-
mation on the three-dimensional nature of the endothelin A recep-
tor binding site which may prove useful for rational drug design. 
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1. Introduction 
Endothelin (ET) is a 21-amino acid polypeptide (Fig. 1 ), 
which is the most potent natural vasoconstrictor yet identified 
[1]. It binds toG-protein coupled receptors in a wide range of 
tissue types and has been linked with a number of diseases, 
including hypertension, myocardial infarction, atherosclerosis 
and renal failure. As such, it has been a target for drug discov-
ery and considerable effort has been expended to develop small 
molecule analogues of it which may prove to be effective antag-
onists [2). 
To rationally design such an antagonist, one would optimally 
have the three-dimensional structure of both the receptor and 
its native ligand. To date, however, there is no detailed struc-
tural information available on the ET receptors nor, indeed, on 
any of the G-protein coupled receptors. There is, however, a 
wealth of structure/activity relationship (SAR) data on the na-
tive ligand and on many synthetic analogues of ET. In addition 
there exists detailed three-dimensional structural information 
on human ET and a number of its analogues and on small 
molecule antagonists. These data, provided they can be ration-
alized in terms of common structural features, should be useful 
in developing an image of the receptor binding pocket features 
which are crucial for ligand binding. In turn, this would provide 
essential data for the rational design of new antagonists. 
A number of structures have been proposed for endothelin: 
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several from NMR studies [3-14) and, recently, one from X-ray 
crystallography [15]. The NMR structures have been from or-
ganic solutions or aqueous/organic solvent mixtures; the X-ray 
structure was from a purely aqueous solution. The NMR and 
X-ray structures differ primarily in the conformation of the 
C-terminal part of the molecule [16]. The C-terminus is essen-
tially a disordered structure in all of the NMR models, but 
forms an irregular, but well-ordered helix in the crystal struc-
ture. The presence of such a helix is also consistent with fluores-
cence studies of the molecule in aqueous solutions [17]. Thus, 
the question has arisen as to which of the NMR or X-ray 
structures can be most useful in providing information on the 
bioactive conformation of the molecule. As the C-terminal res-
idues have been identified as being crucial for receptor binding, 
the importance of the detailed structure of this region of the 
molecule is obvious. One approach to assessing whether the 
structure is a bioactive conformation is to compare it with an 
analogue molecule which is conformationally restricted and 
determine if there is any sensible overlap of crucial chemical 
moieties between the two. 
In 1991, a cyclic pentapeptide isolated from a fermentation 
broth of Streptomyces misakiensis was found to selectively in-
hibit the binding of ET-1 to the endothelin A receptor subtype 
and to functionally antagonize ET-1 induced vasoconstriction 
[18]. This molecule, cyclo(o-Trp-o-Glu-L-Ala-o-Alloile-L-Leu), 
has served as the lead structure from which a number of more 
potent analogues have been derived, most notably BQ123, 
cyclo(o-Trp-o-Asp-L-Pro-o-Val-L-Leu), a potent and highly se-
lective endothelin receptor antagonist (Fig. 2) [19,20]. While the 
sequence of BQ 123 does not match any part of the ET-1 se-
quence, it contains features similar to those at the carboxy-
terminal end, e.g. tryptophan preceded by two hydrophobic 
residues and an aspartic acid, and thus is generally thought to 
mimic this region [20]. 
While no X-ray structure of BQ123 exists, NMR studies of 
this molecule and analogues in a variety of solvents and solvent 
mixtures [22-26] show a remarkably consistent structure for the 
polypeptide backbone (which is defined by a type II P-turn 
containing the leucine and o-tryptophan at positions i + 1 and 
i + 2, respectively, and an inverse y-turn at the proline). The 
side chain positions display strong preferences in hydrophilic 
environments; in particular, a close contact is observed between 
leucine and o-tryptophan. However, in the non-polar solvent 
CDC13, no such preference is observed for the equipotent ana-
logue N-methyl-leucine BQ123 [25]. The collective results sug-
gest a strongly preferred backbone structure with environmen-
tally-dependent sidechain positions. 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
S S D I 0 0 14-5 7 9 3 (9 5 )0 I I 56-0 
380 
The goal of this study was to determine if there is any corre-
spondence between the three-dimensional structures of BQ123 
and its analogues and the C-terminal tail of endothelin-1, par-
ticularly between residues in bothe molecules known for be 
important either for binding or function. It was anticipated that 
if a good correlation could be found, then this might give an 
idea of the region of the structure that was involved in the 
binding site and insight into the geometric nature of the recep-
tor binding pocket, and could thus be useful in the rational 
design of new antagonists. Further it might provide evidence 
as to which of the many structures of the ETC-terminal tail was 
relevant to the endothelin A receptor-bound conformation. 
2. Materials and methods 
The X-ray structure of human ET in crystals prepared from an 
aqueous solution has been previously published [15], and the coordi-
nates deposited in the Brookhaven Protein Data Bank (acquisition code 
IEDN). The structure of N-methyl-leucine BQ123 is a low energy 
structure determined by NMR spectroscopy from solution in CDCI3 
[25]. N-Methyl-leucine BQ123 is a highly active and specific antagonist 
[27] and was chosen for this comparative study because its methyl group 
imposes additional steric constraints, which must be allowed for in any 
binding site model. The residues numbers for BQ123 are denoted with 
a' to distinguish them from the residue numbers in ET. 
Alignments were done graphically to achieve maximal superimposi-
tion of the residue pairs o-Asp2'/Asp18, Lnm5'/Ile20, and o-Trp1'/Trp21 , 
respectively, while maintaining good backbone correspondence. The 
structure of ET-1 was held rigid as was the backbone conformation of 
the peptide antagonist. Only the sidechains of the antagonist were 
allowed to rotate to achieve the overlay. The residue pairs were elected 
on the basis of SAR data highlighting the Asp [28] and Trp [29] residues 
in the peptide antagonists as important to binding affinity, and Asp18, 
Ile20, and Trp21 in ET-1 as important to either binding or function 
[30-32]. Many other potential overlaps were examined, but none pro-
duced as strong a functional correlation as the one discussed here. 
Fig. 3 was produced using the software SETOR [33]. TheN-methyl-
leucine residue is designated Lnm. 
3. Results 
On first inspection, the compositiOn of N-methyl-leucine 
BQ123 and endothelin appear very different: not only is the 
small molecule cyclic in nature, as opposed to the linear C-
terminus of the native peptide, it also includes three amino acids 
with different (D-) chirality, and two conformationally-chal-
lenged imino acids (proline and N-methyl-leucine) not present 
in ET. Despite this, their three-dimensional structures exhibit 
very similar features. In the superposition in Fig. 3, it can be 
seen that the position of the carboxylate group of Asp18 in ET 
corresponds closely to that of o-Asp2' in BQ123, whilst the 
sidechains of the pairs Ile20/Lnm5' and Trp21 /o-Trp1' also over-
lap well (note: in the figure, the fl-y bond of Asp18 is rotated 
to clarify the correspondence between the carboylate groups). 
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Fig. I. Amino acid sequence of human endothelin-1. 
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Fig. 2. Chemical structure of the endothelin receptor antagonist BQ123. 
With this correspondence, several antagonist backbone ele-
ments can also be aligned, notably the carbonyl groups ofVal3. 
and Lnm5' to those oflle19 and Ile20 ofET-1, respectively. This 
may be, in part, because the ET helix, as stated earlier, is 
irregular, with some distorted ¢, rp angles, and not all the ex-
pected hydrogen-bonds formed. Had the helix been more 'per-
fect' the overlap with the small molecule may not have been as 
good. The overlap between the structures of BQ123 and the 
C-terminal five amino acids of ET is excellent as found in the 
crystal structure, but the same cannot be said for any of the 
NMR structures, because they do not contain helical C-termini. 
The side chains that are believed to be important for binding 
based on SAR studies, notably residues 18 and 21, overlap very 
well even though the backbone conformations of the two mol-
ecules are different, and hence their overlap not particularly 
good. The backbones of the two molecules veer off in different 
directions in the region of the molecule between residues 18 and 
21. This allows both the o-amino acid sidechains of Asp2' and 
Trp 1' in BQ123 to line up with the L-amino acids of Asp18 and 
Trp21 in ET, whilst the L-Ile20 sidechain can still point in the 
same direction as L-Lnm5'. The consequence of this is that there 
is not a one-to-one correspondence of the Pro3' and Val4' resi-
dues of BQ123 with residues in ET. Similarly, there is no obvi-
ous counterpart in ET for the N-methyl group in N-methyl-
leucine. The surface features of the two molecules, which are 
expected to be those recognized by the receptor, are very similar 
despite the differences in the buried parts of the molecules. 
Other superpositions (especially when only Ca atoms are 
used in alignment algorithms) produce better correspondences 
of the backbone, but in those cases, none of the sidechains 
overlap, and the surface contours are entirely different. 
It should be noted that obtaining the superposition of these 
molecules only required the rotation of the side chains in the 
smaller molecule. It was not necessary to invoke molecular 
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Fig. 3. Two stereo-views showing the overlay of N-methy1-1eucine BQ123 (in green) and residues 17-21 of human endothe1in-l (as found in the crystal 
structure [15] (in grey). 
dynamics simulations for either peptide. In fact, no alteration 
of the ET-1 X-ray coordinates was required. 
The advantage of dealing with the structure of a small mole-
cule in drug design is that it may be much more conformation-
ally restrained than is the native peptide, so there is a limit to 
the range of possible structures that it may adopt in order to 
fit into a receptor binding site. In the case of BQ123, the con-
straints are imposed by its small size, the presence of the confor-
mationally restricting amino acid proline, the stereochemical 
variations at the Ca positions, and the cyclic nature of the 
peptide. As a consequence, all the NMR studies have produced 
very similar structures for this small molecule. Thus there is 
little freedom in the choice of possible structures to be used for 
the comparisons. 
4. Discussion 
Three naturally-occurring isoforms of endothelin have been 
identified, ET-1, ET-2, ET-3, which are highly homologous, 
differing only in the nature of2-5 amino acids in theN-terminal 
part of the molecule. The C-terminal seven amino acids are 
identical in all isoforms, and amino acid substitutions as well 
as alanine scan studies have indicated the importance of the 
C-terminal amino acids in receptor binding. SAR studies on 
peptide and non-peptide small molecule antagonists have 
pointed to the importance of a juxtaposition of an acidic group 
(presumably Asp 18 in the native endothelin) and at least one 
aromatic group (in native ET this would likely be Trp21 ). Thus, 
it was postulated that these types of side chains should be in 
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similar relative positions in both the small molecule and in the 
native peptide [34]. In BQ123 the corresponding groups would 
appear to be o-Asp2' and o-Trp1'. Although there are a number 
of possible acidic/aromatic combinations in ET-1, SAR studies 
for both molecules support a correspondence ofBQ123 and its 
analogues to the C-terminal tail of ET-1. 
The overlay studies reported here would suggest that the 
endothelin A receptor binding site has a geometry that would 
accommodate the tryptophan side chain as well as a closely 
juxtaposed carboxylate from the aspartic acid sidechain, but 
that the residues on the opposite side of the molecule (i.e. 
residues 17 and 19 of ET-1 and Pro3' and Val4' of BQ 123) are 
not the primary sources of contact with the receptor. 
The endothelin A receptor (ETA) is selective in its binding of 
the endothelin isoforms such that ET-1 = ET-2 >> ET-3; the 
endothelin B receptor (ETa) binds all isoforms with nearly 
equal affinity. There is an apparent paradox in suggesting that 
BQ123, an ETA selective antagonist, overlays a region of the 
endothelins found through analogue studies to be important for 
the binding of both ETA and ETa· Recent mutagenesis data 
suggest that a residue located in transmembrane segment 2 of 
ETA affects the selectivity of ETA for agonist peptides as well 
as its affinity for BQ123. However, modification of the corre-
sponding residue in ETa does not alter the non-selective profile 
of this receptor subtype, nor does it confer affinity for BQ 123. 
Selectivity, therefore, does not appear to arise in this system 
from an easily identified set of interactions. If, however, as this 
study suggests, BQ123 and its analogues overlay the part of the 
isoforms that have a common sequence, then the differences in 
isoform binding affinities may arise from the regions where 
their sequences differ, notably residue 2 and the region from 
residue 4 to residue 7. The far lower binding affinity of ET-3 
for the endothelin A receptor may well be caused by steric 
hindrances that lie outside the binding site indicated in this 
study. 
Even though it is now widely believed that BQ123 mimics the 
C-terminus of ET [21], earlier studies by Satoh and Barlow [35] 
which had compared model structures for BQ123 with the 
NMR structure of endothelin, suggested an alternative corre-
spondence might exist between BQ123 and residues 6-8 of the 
ET polypeptide. However, that work was done prior to the 
availability of the ET crystal structure, the NMR structures of 
BQ123, and the wealth ofSAR data now in hand. The confor-
mation of the central turn region of ET which was their pro-
posed region of correspondence, now appears in both the NMR 
and crystal structures to be somewhat different from the one 
used in their comparison study. In addition, their overlap with 
the N-terminus of endothelin does not take into account the 
crucial nature of the C-terminal residues. 
Future work will entail comparisons of the ET structure with 
other synthetic peptide and non-peptide antagonists for the 
endothelin receptors, and in this way build up a more complete 
view of the nature of the binding pocket. Initial attempts to 
design small molecule antagonists from the BQ peptide series 
alone has produced compounds with only moderate affinity 
[29], indicating the need for a more complete description of the 
cyclic pentapeptide binding site. Our comparison ofBQ123 and 
the C-terminus of ET has provided important information on 
the nature of the binding site geometric requirements, and given 
support to the notion that the crystal structure of ET may 
represent a bioactive receptor-bound conformation. In addi-
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tion, it emphasizes the notion previously suggested [15,36] that 
one surface of the ETC-terminal helix, which includes residues 
18 and 21 and arises from consecutive turns of the helix, is very 
important for receptor binding. 
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